The RAISE Trial: A Novel Device and First-in-Man Trial

Author:

Sun Wei12ORCID,Zou Huayiyang1,Yong Yonghong1,Liu Boxun1,Zhang Hao1,Lu Jieyu1,Shen Yihui1ORCID,Li Peng1ORCID,Xu Tianhua1,Chen Xuguan1,Du Anning1,Jiang Ming1,Hua Yang1,Sheng Yanhui1,Zhou Bin13ORCID,Lotan Chaim4,Kong Xiangqing123ORCID

Affiliation:

1. Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, China (W.S., H. Zou, Y.Y., B.L., H. Zhang, J.L., Y. Shen, P.L., T.X., X.C., A.D., M.J., Y.H., Y. Sheng, B.Z., X.K.).

2. Cardiovascular Device and Technique Engineering Laboratory of Jiangsu Province, Nanjing, China (W.S., X.K.).

3. State Key Laboratory of Reproductive Medicine, Nanjing Medical University, China (B.Z., X.K.).

4. Heart Institute, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (C.L.).

Abstract

Background: Currently, standard medical therapies have limited effects on heart failure with preserved ejection fraction (HFpEF), which impacts on the life quality and survival of patients. This study aimed to evaluate the safety and efficacy of the percutaneous radiofrequency ablation–based interatrial shunting for HFpEF with a novel atrial septostomy device. Methods: A preclinical study in 11 normal domestic pigs and the first-in-man study in 10 patients with HFpEF were performed. The major safety events and interatrial shunt performance were evaluated at baseline, 1 month, 3 months, and 6 months post-procedure in both animals and human patients. The clinical functional status was also assessed in the first-in-man study. Results: Percutaneous radiofrequency ablation–based interatrial shunting therapy was performed successfully both in animals and patients. In the animal study, a left-to-right interatrial shunt was created with a mean defect size of 5.5±2.2 mm without procedure-related safety events. Seven pigs showed the continuous shunting with a mean defect size of 4.1±1.5 mm at 6 months. In the first-in-man study, a median interatrial defect diameter of 5.0 (4.0–6.0) mm was measured immediately. No major safety events including death and thromboembolism were observed. The continuous shunting with the defect size of 4.0 (3.0–4.0) mm could still be observed in 7 patients at 6 months. The clinical status was significantly improved with NT-proBNP (N-terminal pro-B-type natriuretic peptide) reduced by 2149 pg/mL ([95% CI, 204–3301] P =0.028), with 6-minute walk distance increased by 88 m ([95% CI, 50–249] P =0.008) and with New York Heart Association class improved in 8 patients at 6 months. Conclusions: The present results showed that percutaneous radiofrequency ablation–based interatrial shunting was a safe and potentially effective therapy for HFpEF, providing a nonpharmacological and nonimplanted option for HFpEF management. Registration: URL: https://www.chictr.org.cn ; Unique identifier: ChiCTR1900027664.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3